with which it signed a licensing deal earlier this year to sell its COVID vaccine from 2025 in several markets, including the ...

The XEC COVID-19 variant is poised to become the dominant variant worldwide. Now is a good time to get an updated COVID ...

COVID-19 vaccination coverage has progressed unevenly throughout the world. Moreover, 1.01 and 1.43 doses for each person are ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

An opponent of vaccines who wrote social media posts urging violence against scientists, politicians and public health officials during the COVID-19 pandemic was sentenced Monday to five ...

With so many gaps in global vaccine coverage, there was a 60 per cent increase in the number of significant measles outbreaks ...

Pfizer-BioNTech, Johnson and Johnson, and Moderna said their vaccines prevented severe illness and hospitalization in COVID-19 cases caused by the variant ... in June 2024 and rapidly spread ...

The death of three young Nashville area runners in the past three months have raised questions this TSSAA cross country ...

On their book that explores how societies worldwide responded to plague pandemics from Constantinople in the sixth century to ...

While over 20 percent of European COVID-19 tests come back positive ... two to 20 times more cases than that. There is a new ...

Arcturus Therapeutics (ARCT) is continuing to evaluate the use of LUNAR-CF [ARCT-032] for the treatment of patients with Cystic Fibrosis [CF]. Read our latest report on the stock here.

The optimal pricing strategy for a new vaccine ... the impact of COVID-19 on biopharmaceutical market access through interviews conducted with payers and advisors in the US, Europe, Brazil ...